Advancing the portfolio of tuberculosis diagnostics, drugs, biomarkers, and vaccines

The Lancet Infectious Diseases

Volumn 14, Issue 4, 2014, Pages 267-269

  Zumla, Alimuddin I ^a,b   Schito, Marco ^c   Maeurer, Markus ^d,e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DISEASE ACTIVITY; EPIDEMIC; HUMAN; NOTE; NUCLEIC ACID AMPLIFICATION; PRIORITY JOURNAL; SPUTUM CYTODIAGNOSIS; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS CONTROL;

BIOLOGICAL MARKERS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY;

EID: 84896464785     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70028-3     Document Type: Note

References (19)

1. World Health Organisation Global Tuberculosis report WHO, (accessed Nov 12, 2013). http://www.who.int/tb/publications/global_report/en/.
2. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013, 42:169-179.
3. TB-a global emergency. WHO Press Release 1993, WHO, World Health Organization, Geneva.
4. Pietersen E, Ignatius E, Streicher EM, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet 2014, published online Jan 16. http://dx.doi.org/10.1016/S0140-6736(13)62675-6.
5. Dheda K, Migliori GB The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue?. Lancet 2012, 379:773-775.
6. Hughes J, Cox H Sanatoria for drug-resistant tuberculosis: an outdated response. Lancet 2012, 379:2148.
7. Zumla A, George A, Sharma V, Herbert N WHO's 2013 global report on tuberculosis: successes, threats, and opportunities. Lancet 2013, 382:1765. Baroness Masham of Ilton, 57.
8. Kaufmann SHE, Lange C, Rao M, et al. Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review. Lancet Respir Med 2014, published online March 24. http://dx.doi.org/10.1016/S2213-2600(14)70033-5.
9. Lawn SD, Mwaba P, Bates M, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 2013, 13:349-361.
10. Zumla A, Nahid P, Cole ST Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013, 12:388-404.
11. Zumla A, Gillespie SH, Hoelscher M, et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis 2014, published online March 24. http://dx.doi.org/10.1016/S1473-3099(13)70328-1.
12. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013, 381:1021-1028. for the MVA85A 020 Trial Study Team.
13. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2014, 1. CD009593.
14. Lawn SD, Dheda K, Kerkhoff AD, et al. Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies. BMC Infect Dis 2013, 13:407.
15. Theron G, Zijenah L, Chanda D, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 2013, 382:424-435.
16. Theron G, Peter J, Dowdy D, Langley I, Squire SB, Dheda K Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings?. Lancet Infect Dis 2014, published online Jan 14. http://dx.doi.org/10.1016/S1473-3099(13)70360-8.
17. Zumla A, Gant V, Bates M, Mwaba P, Maeurer M, Memish ZA Rapid diagnostics urgently needed for killer infections. Lancet Respir Med 2013, 1:284-285.
18. Joosten SA, Fletcher HA, Ottenhoff TH A helicopter perspective on TB biomarkers: pathway and process based analysis of gene expression data provides new insight into TB pathogenesis. PLoS One 2013, 8:e73230.
19. Zumla A, Mwaba P, Huggett J, Kapata N, Chanda D, Grange J Reflections on the white plague. Lancet Infect Dis 2009, 9:197-202.